Image from Google Jackets

A new monoclonal antibody treats severe asthma / Diane S. Aschenbrenner

By: Series: American Journal of Nursing. 116 : 7, page 24-25 Publication details: July 2016.Content type:
  • text.
Media type:
  • unmediated.
Carrier type:
  • volume.
ISSN:
  • 0002-936X
Subject(s): Summary: * Reslizumab (Cinqair), a new human monoclonal antibody, has been approved to treat severe asthma in adults. Given intravenously, the drug is used as adjunct therapy, in conjunction with inhaled corticosteroids, to reduce the frequency of asthma exacerbations, relieve asthma symptoms, and improve lung function in patients with elevated blood eosinophil levels. * Like all monoclonal antibodies, it carries a risk of anaphylaxis.
Item type: Articles
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Current library Call number Status Date due Barcode
Manila Tytana Colleges Library REFERENCE SECTION Not For Loan

* Reslizumab (Cinqair), a new human monoclonal antibody, has been approved to treat severe asthma in adults. Given intravenously, the drug is used as adjunct therapy, in conjunction with inhaled corticosteroids, to reduce the frequency of asthma exacerbations, relieve asthma symptoms, and improve lung function in patients with elevated blood eosinophil levels. * Like all monoclonal antibodies, it carries a risk of anaphylaxis.

Nursing

There are no comments on this title.

to post a comment.
Manila Tytana Colleges Library | Metropolitan Park, Pres. Diosdado Macapagal Blvd., Pasay City, 1300
Tel.(+63-2) 859-0826 | E-mail library@mtc.edu.ph